Literature DB >> 12206845

The evolution and state of modern technology for prostate cryosurgery.

John C Saliken1, Bryan J Donnelly, John C Rewcastle.   

Abstract

Cryosurgery is the in situ ablation of a target tissue by application of extreme cold temperature. The ability of cryosurgery to ablate tissue is unquestioned. It is the controlled application of a cryoinjury in a manner to minimize morbidity that is problematic. Prostate cryosurgery is complicated by the proximity of the prostate to adjacent structures that are sensitive to a freeze injury, namely the urethra, rectal wall, and neurovascular bundles. Several recent technological advances have led to the development of an effective treatment protocol with acceptable morbidity. These include the advent of real-time transrectal ultrasound, cryomachines with almost instant freeze-thaw control through the use of the Joule-Thompson effect, and warming catheters to effectively preserve the integrity of the urethra and external sphincter. Further, temperature monitoring at the posterior margin of the prostate sometimes combined with an injection of saline solution into Denonvilliers fascia has reduced the occurrence of urethrorectal fistula formation to 0% to 0.5% in modern series. We review the key innovations of prostate cryosurgery that differentiate this state-of-the-art procedure from that used by early investigators to even that of the early 1990s. Potential future innovations, specifically related to image guidance of the procedure, are also addressed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12206845     DOI: 10.1016/s0090-4295(02)01681-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  17 in total

Review 1.  Cryotherapy.

Authors:  Katsuto Shinohara
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

Review 2.  Re-purposing cryoablation: a combinatorial 'therapy' for the destruction of tissue.

Authors:  J G Baust; J C Bischof; S Jiang-Hughes; T J Polascik; D B Rukstalis; A A Gage; J M Baust
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-01-27       Impact factor: 5.554

3.  Treatment- and disease-related complications of prostate cancer.

Authors:  Anne R Simoneau
Journal:  Rev Urol       Date:  2006

4.  New techniques and management options for localized prostate cancer.

Authors:  Joycelyn L Speight; Mack Roach
Journal:  Rev Urol       Date:  2006

5.  CT-guided percutaneous cryoablation of renal masses in selected patients.

Authors:  C Spreafico; N Nicolai; R Lanocita; C Morosi; M Catanzaro; E Civelli; T Torelli; S Stagni; L Piva; L F Frigerio; A Marchianò; R Salvioni
Journal:  Radiol Med       Date:  2011-10-21       Impact factor: 3.469

6.  Pre-conditioning cryosurgery: cellular and molecular mechanisms and dynamics of TNF-α enhanced cryotherapy in an in vivo prostate cancer model system.

Authors:  Jing Jiang; Raghav Goel; Stephen Schmechel; Gregory Vercellotti; Colleen Forster; John Bischof
Journal:  Cryobiology       Date:  2010-10-20       Impact factor: 2.487

7.  Salvage Cryoablation for Radiorecurrent Prostate Cancer: Initial Experience at a Regional Health Care System.

Authors:  Seena Safavy; Ramzi B Jabaji; Sharon M Lu; Jeff M Slezak; Harry A Cosmatos; Stephen G Williams; David S Finley
Journal:  Perm J       Date:  2019

8.  Effects of prostate-rectum separation on rectal dose from external beam radiotherapy.

Authors:  Robert C Susil; Todd R McNutt; Theodore L DeWeese; Danny Song
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-11-24       Impact factor: 7.038

Review 9.  Locally ablative therapies for primary radiation failures: a review and critical assessment of the efficacy.

Authors:  William C Huang; Courtney L Lee; James A Eastham
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

Review 10.  Adjuvant approaches to enhance cryosurgery.

Authors:  Raghav Goel; Kyle Anderson; Joel Slaton; Franz Schmidlin; Greg Vercellotti; John Belcher; John C Bischof
Journal:  J Biomech Eng       Date:  2009-07       Impact factor: 2.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.